Acadia Pharmaceuticals (ACAD) Accumulated Expenses (2010 - 2026)

Acadia Pharmaceuticals' Accumulated Expenses history runs 17 years deep, the most recent figure standing at $31.4 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 88.95% year-over-year to $31.4 million in Q1 2026; TTM through Mar 2026 was $31.4 million, a 88.95% decrease from a year earlier, with the FY2025 full-year figure at $266.2 million, up 628.33% from the prior year.
• Accumulated Expenses slipped to $31.4 million in Q1 2026 per ACAD's latest filing, from $266.2 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $334.8 million in Q3 2025 and bottomed at $21.2 million in Q1 2023.
• The 5-year median for Accumulated Expenses is $105.8 million (2022), against an average of $134.4 million.
• Across the five-year window, Accumulated Expenses soared 1368.79% in 2024 and sank 90.95% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $28.0 million in 2022, then jumped by 52.44% to $42.7 million in 2023, then decreased by 14.44% to $36.6 million in 2024, then soared by 628.33% to $266.2 million in 2025, then tumbled by 88.19% to $31.4 million in 2026.
• Per Business Quant, the three latest ACAD Accumulated Expenses figures stand at $31.4 million (Q1 2026), $266.2 million (Q4 2025), and $334.8 million (Q3 2025).